Fmr LLC Adicet Bio, Inc. Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Adicet Bio, Inc. stock. As of the latest transaction made, Fmr LLC holds 210,266 shares of ACET stock, worth $262,832. This represents 0.0% of its overall portfolio holdings.

Number of Shares

210,266

Previous 194,201 8.27%

Holding current value

$262,832

Previous $456,000 44.3%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$1.21 - $2.4 $19,438 - $38,556	16,065 Added 8.27%	210,266 $254,000
Q1 2024 May 13, 2024	BUY	$1.76 - $3.45 $102,585 - $201,090	58,287 Added 42.89%	194,201 $456,000
Q4 2023 Feb 13, 2024	SELL	$1.11 - $1.89 $93 - $158	-84 Reduced 0.06%	135,914 $256,000
Q3 2023 Nov 13, 2023	BUY	$1.37 - $3.4 $88,956 - $220,768	64,932 Added 91.37%	135,998 $186,000
Q2 2023 Aug 11, 2023	BUY	$2.13 - $7.13 $147,849 - $494,914	69,413 Added 4199.21%	71,066 $172,000
Q1 2023 May 11, 2023	SELL	$5.52 - $9.23 $3.1 Million - $5.19 Million	-561,880 Reduced 99.71%	1,653 $9,000
Q4 2022 Feb 13, 2023	SELL	$7.72 - $21.27 $1.9 Million - $5.23 Million	-245,818 Reduced 30.37%	563,533 $5.04 Million
Q3 2022 Nov 10, 2022	BUY	$13.43 - $18.74 $2,981 - $4,160	222 Added 0.03%	809,351 $11.5 Million
Q2 2022 Aug 12, 2022	BUY	$10.26 - $20.81 $2.47 Million - $5.01 Million	240,563 Added 42.31%	809,129 $11.8 Million
Q1 2022 May 13, 2022	BUY	$11.53 - $19.97 $3.51 Million - $6.09 Million	304,801 Added 115.56%	568,566 $11.4 Million
Q4 2021 Feb 14, 2022	BUY	$7.37 - $17.49 $1.94 Million - $4.61 Million	263,765 New	263,765 $4.61 Million

Others Institutions Holding ACET

# of Institutions

Shares Held

66.3M

Call Options Held

4.3K

Put Options Held

36.3K

View Full List

About Adicet Bio, Inc.

Ticker ACET
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,030,800
Market Cap $50M
Description
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune respo...

More about ACET

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account